Federated Hermes
PCVX icon

Federated Hermes’s Vaxcyte PCVX Stock Holding History

Federated Hermes’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.9M Buy
601,161
+34,333
+6% +$1.86M 0.05% 349
2026
Q1 		$32.9M Buy
566,828
+43,339
+8% +$2.35M 0.05% 355
2025
Q4 		$24.2M Buy
523,489
+505,333
+2,783% +$22.6M 0.04% 409
2025
Q3 		$654K Buy
18,156
+17,895
+6,856% +$593K ﹤0.01% 1271
2025
Q2 		$8.48K Buy
+261
New +$8.56K ﹤0.01% 1837
2025
Q1 		– Sell
-326,058
Closed -$26.7M – 2168
2024
Q4 		$26.7M Sell
326,058
-174,992
-35% -$17.4M 0.06% 351
2024
Q3 		$57.3M Buy
501,050
+75,410
+18% +$6.8M 0.13% 212
2024
Q2 		$32.1M Sell
425,640
-110
-0% -$7.49K 0.08% 293
2024
Q1 		$29.1M Buy
425,750
+31,558
+8% +$2.19M 0.07% 336
2023
Q4 		$24.8M Sell
394,192
-1,615
-0.4% -$83.9K 0.06% 341
2023
Q3 		$20.2M Sell
395,807
-627
-0.2% -$30.9K 0.05% 365
2023
Q2 		$19.8M Buy
396,434
+319,521
+415% +$15.1M 0.05% 390
2023
Q1 		$2.88M Buy
76,913
+76,694
+35,020% +$3.25M 0.01% 842
2022
Q4 		$10.5K Buy
+219
New +$8.59K ﹤0.01% 1861

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Federated Hermes's PCVX Position: Q2 2026 in Review

Federated Hermes increased its Vaxcyte (PCVX) stake by 6.1% in Q2 2026, buying an estimated $1.86M and bringing the position to 601,161 shares worth $34.9M. The position accounts for 0.05% of the portfolio, ranked #349.

Federated Hermes first reported a position in PCVX in Q4 2022 and has held it in 14 quarters since. The position peaked at $57.3M in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Federated Hermes held 601,161 shares of Vaxcyte worth $34.9M as of Q2 2026.
  • Federated Hermes bought 34,333 Vaxcyte shares in Q2 2026, an estimated $1.86M.
  • Vaxcyte made up 0.05% of Federated Hermes's portfolio in Q2 2026, its #349 holding.
  • Federated Hermes first reported a position in Vaxcyte in Q4 2022 and has held it in 14 quarters since.
  • Federated Hermes's Vaxcyte position peaked at $57.3M in Q3 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.